137 related articles for article (PubMed ID: 12016395)
1. Outstanding problems with response evaluation criteria in solid tumors (RECIST) in breast cancer.
Kimura M; Tominaga T
Breast Cancer; 2002; 9(2):153-9. PubMed ID: 12016395
[TBL] [Abstract][Full Text] [Related]
2. [New guidelines to evaluate the response to treatment "RECIST"].
Sasaki T
Gan To Kagaku Ryoho; 2000 Dec; 27(14):2179-84. PubMed ID: 11142160
[TBL] [Abstract][Full Text] [Related]
3. Comparison of WHO and RECIST criteria for evaluation of clinical response to chemotherapy in patients with advanced breast cancer.
Khokher S; Qureshi MU; Chaudhry NA
Asian Pac J Cancer Prev; 2012; 13(7):3213-8. PubMed ID: 22994736
[TBL] [Abstract][Full Text] [Related]
4. Tumor growth kinetics versus RECIST to assess response to locoregional therapy in breast cancer liver metastases.
Seyal AR; Parekh K; Velichko YS; Salem R; Yaghmai V
Acad Radiol; 2014 Aug; 21(8):950-7. PubMed ID: 24833565
[TBL] [Abstract][Full Text] [Related]
5. A statistical simulation study finds discordance between WHO criteria and RECIST guideline.
Mazumdar M; Smith A; Schwartz LH
J Clin Epidemiol; 2004 Apr; 57(4):358-65. PubMed ID: 15135836
[TBL] [Abstract][Full Text] [Related]
6. Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients.
Watanabe H; Yamamoto S; Kunitoh H; Sekine I; Yamamoto N; Ohe Y; Tamura T; Kodama T; Sugimura K; Saijo N
Cancer Sci; 2003 Nov; 94(11):1015-20. PubMed ID: 14611681
[TBL] [Abstract][Full Text] [Related]
7. Measuring response in solid tumors: comparison of RECIST and WHO response criteria.
Park JO; Lee SI; Song SY; Kim K; Kim WS; Jung CW; Park YS; Im YH; Kang WK; Lee MH; Lee KS; Park K
Jpn J Clin Oncol; 2003 Oct; 33(10):533-7. PubMed ID: 14623923
[TBL] [Abstract][Full Text] [Related]
8. Comparing RECIST with EORTC criteria in metastatic bladder cancer.
Öztürk H
J Cancer Res Clin Oncol; 2016 Jan; 142(1):187-94. PubMed ID: 26208817
[TBL] [Abstract][Full Text] [Related]
9. The Attenuation Distribution Across the Long Axis of Breast Cancer Liver Metastases at CT: A Quantitative Biomarker for Predicting Overall Survival.
Abramson RG; Lakomkin N; Hainline A; Kang H; Hutson MS; Arteaga CL
AJR Am J Roentgenol; 2018 Jan; 210(1):W1-W7. PubMed ID: 29064750
[TBL] [Abstract][Full Text] [Related]
10. Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer.
Yoshida S; Miyata Y; Ohtsu A; Boku N; Shirao K; Shimada Y
Gastric Cancer; 2000 Dec; 3(3):128-133. PubMed ID: 11984725
[TBL] [Abstract][Full Text] [Related]
11. [CT evaluation of response to chemotherapy and/or radiotherapy in primary lung cancer: comparison of response evaluation criteria in solid tumors (RECIST) and the WHO criteria, and comparison of both methods with the histological evaluation].
Konishi K; Kuriyama K; Chino S; Isohashi K; Murata M; Tsuda K; Mitani T; Maeda M; Kadota T; Arisawa J
Nihon Igaku Hoshasen Gakkai Zasshi; 2004 Jan; 64(1):41-5. PubMed ID: 14994510
[TBL] [Abstract][Full Text] [Related]
12. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
[TBL] [Abstract][Full Text] [Related]
13. RECIST revisited: a review of validation studies on tumour assessment.
Therasse P; Eisenhauer EA; Verweij J
Eur J Cancer; 2006 May; 42(8):1031-9. PubMed ID: 16616487
[TBL] [Abstract][Full Text] [Related]
14. Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases.
Monetti F; Casanova S; Grasso A; Cafferata MA; Ardizzoni A; Neumaier CE
Lung Cancer; 2004 Jan; 43(1):71-4. PubMed ID: 14698539
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer.
Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Oh ST; Kim JG; Choi MH; Lee MA
Cancer Res Treat; 2018 Jan; 50(1):283-292. PubMed ID: 28494536
[TBL] [Abstract][Full Text] [Related]
16. Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer.
Riedl CC; Pinker K; Ulaner GA; Ong LT; Baltzer P; Jochelson MS; McArthur HL; Gönen M; Dickler M; Weber WA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1428-1437. PubMed ID: 28462446
[TBL] [Abstract][Full Text] [Related]
17. [Activity, objective response, and WHO and RECIST (Response Evaluation Criteria In Solid Tumor) evaluation criteria].
De Angelis V
Suppl Tumori; 2004; 3(4):S7-9. PubMed ID: 15206198
[No Abstract] [Full Text] [Related]
18. Stratifying the outcome after neoadjuvant treatment using pathological response classification by the Japanese Breast Cancer Society.
Mukai H; Arihiro K; Shimizu C; Masuda N; Miyagi Y; Yamaguchi T; Yoshida T
Breast Cancer; 2016 Jan; 23(1):73-77. PubMed ID: 26423822
[TBL] [Abstract][Full Text] [Related]
19. Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy: comparison of RECIST, Choi and volumetric criteria.
Schramm N; Englhart E; Schlemmer M; Hittinger M; Übleis C; Becker CR; Reiser MF; Berger F
Eur J Radiol; 2013 Jun; 82(6):951-8. PubMed ID: 23518148
[TBL] [Abstract][Full Text] [Related]
20. [Value of dual-energy CT-based volumetric iodine-uptake in the evaluation of chemotherapy efficacy in advanced gastric cancer].
Chen LF; Fu GZ; Huang DP; Man Y; Jin Y; Dong QT; Huang YB; Chen YC; Wang HQ
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Oct; 22(10):977-983. PubMed ID: 31630497
[No Abstract] [Full Text] [Related]
[Next] [New Search]
